Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.

British journal of cancer - 8 Nov 2016

Konecny G E, Kristeleit R S

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality. PARP inhibitors are being evaluated in late-stage clinical trials of ovarian cancer (OC). Recently, olaparib was the first PARP inhibitor approved in the European Union and United States for the treatment of advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 gene

Share to Mutation

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Open in PubMed Open full text

Identifiers

PMID: 27736844
DOI: 10.1038/bjc.2016.311
PMCID: PMC5104889

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.PMID 27736844Read ↗

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.Semantic proximity Read ↗

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersSemantic proximity Read ↗

The current status of PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.Semantic proximity Read ↗

PARP inhibitors: A new era of targeted therapy.Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian CancerSemantic proximity Read ↗

PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.